Amgen initiates study into heart failure and anemia
6th Sep 2005, 01:02 GMT
US biotech firm Amgen is to initiate a late stage trial into the effect of its anemia treatment, darbepoetin alfa, in patients with heart failure. The company hopes to produce a reduction in mortality and hospitalization in this patient group.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol